By Ben Glickman

AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share, giving the company an equity value of about $8.7 billion.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

December 06, 2023 16:50 ET (21:50 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more AbbVie Charts.